Literature DB >> 16442389

Hospital resources consumed in treating complications associated with percutaneous coronary interventions.

Aaron D Kugelmass1, David J Cohen, Phillip P Brown, April W Simon, Edmund R Becker, Steven D Culler.   

Abstract

Nearly 9.5% of all Medicare beneficiaries who undergo a percutaneous coronary intervention (PCI) procedure develop > or =1 of 7 acute complications. This study used 2 approaches (regression analysis and propensity-matched samples) to estimate the cost of selected complications, based on administrative data from 335,477 Medicare beneficiaries who underwent PCI during a hospitalization in fiscal year 2002. Selected complications included hospital mortality, emergency/urgent coronary artery bypass surgery, postoperative stroke, acute renal failure, vascular complications, septicemia, and adult respiratory distress syndrome. The observed average cost of a PCI hospitalization for patients who did not develop complications was 13,861 dollars +/- 9,635 dollars, with an average length of stay of 3.0 +/- 3.2 days, compared with 26,807 dollars +/- 27,596 dollars and 8.0 +/- 8.9 days for patients who did develop complications. Estimates of the adjusted incremental hospital cost of treating any acute complication except death varied from a high of 33,030 dollars for patients who developed septicemia to a low of 4,278 dollars for those who developed vascular complications, whereas estimates of the incremental length of stay ranged from a high of 12.3 days for patients who had septicemia to a low of 1.8 days for patients who had vascular complications. In conclusion, we found that the incremental hospital resources that are consumed to treat patients with acute PCI complications are large compared with the cost of an uncomplicated PCI hospitalization.

Entities:  

Mesh:

Year:  2006        PMID: 16442389     DOI: 10.1016/j.amjcard.2005.08.047

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Achieving safe femoral arterial access.

Authors:  Michael S Lee; Jeremy Kong
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

Review 2.  Systematic review and cost-benefit analysis of radial artery access for coronary angiography and intervention.

Authors:  Matthew D Mitchell; Jaekyoung A Hong; Bruce Y Lee; Craig A Umscheid; Sarah M Bartsch; Creighton W Don
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-06-26

3.  Bleeding avoidance strategies. Consensus and controversy.

Authors:  Harold L Dauerman; Sunil V Rao; Frederic S Resnic; Robert J Applegate
Journal:  J Am Coll Cardiol       Date:  2011-06-28       Impact factor: 24.094

4.  The economic burden of complications during percutaneous coronary intervention.

Authors:  Kurt M Jacobson; Kirsten Hall Long; Erin K McMurtry; James M Naessens; Charanjit S Rihal
Journal:  Qual Saf Health Care       Date:  2007-04

5.  A cost-minimization analysis of the angio-seal vascular closure device following percutaneous coronary intervention.

Authors:  Frederic S Resnic; Nipun Arora; Michael Matheny; Matthew R Reynolds
Journal:  Am J Cardiol       Date:  2007-01-22       Impact factor: 2.778

6.  Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome.

Authors:  Emad Abu-Assi; Sergio Raposeiras-Roubin; Pamela Lear; Pilar Cabanas-Grandío; Mar Girondo; Marta Rodríguez-Cordero; Eva Pereira-López; Santiago Gestal Romaní; Cristina González-Cambeiro; Belén Alvarez-Alvarez; José María García-Acuña; José Ramón González-Juanatey
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-09

7.  A Randomized Trial Comparing Short versus Prolonged Hemostasis with Rescue Recanalization by Ipsilateral Ulnar Artery Compression: Impact on Radial Artery Occlusion-The RESCUE-RAO Trial.

Authors:  Dmitrii V Ognerubov; Alexander Sedaghat; Sergey I Provatorov; Andrey S Tereshchenko; Olivier F Bertrand; Ivo Bernat; Goar K Arutyunyan; Olga A Pogorelova; Maria I Tripoten; Tatyana V Balakhonova; Anatoliy N Samko; Evgeny V Merkulov
Journal:  J Interv Cardiol       Date:  2020-10-23       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.